Advances in the Diagnosis and Treatment of Nail Unit Melanoma

The presentation discusses nail unit melanoma, a rare yet critical condition as it accounts for 20% of cutaneous melanomas in people with skin of color and has a significantly poorer prognosis compared to cutaneous melanomas. The five-year survival rate for nail unit melanoma averages only 30%, contrasted with 70-90% for other types. Key initial signs include longitudinal melanonychia, dark bands on the nail, and specific ominous markers like Hutchinson's sign. Dermoscopy is essential for diagnosis, revealing irregular characteristics of pigmentation which help in distinguishing melanoma from benign conditions. Techniques for biopsy, notably tangential matrix excision, are emphasized for their effectiveness in obtaining necessary tissue samples with minimal nail dystrophy. The presentation also highlights that histopathological features and specific mutations—like BRAF, KIT, and NRAS—play a crucial role in diagnosing and treating nail unit melanoma. Historical treatment methods have evolved from amputation to end block excisions, which maintain patient functionality without compromising local recurrence rates. Advanced melanoma is treated with targeted therapies based on genetic mutations. The speaker calls for more dedicated clinical trials for nail unit melanoma due to the rarity of the condition and variability in treatment outcomes. Key takeaways cover how to differentiate between benign and malignant conditions using bandwidth percentage, the importance of thorough biopsy procedures, and tailored therapeutic approaches for both thin and advanced melanomas.